After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
These in-demand skills can command top pay packets, says Feon Ang of professional networking site LinkedIn.Get Aheadread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
Ford is one of four automakers that reached a voluntary agreement with California on fuel efficiency rules, defying Trump and his administration's effort to strip the state of...Autosread more
See which stocks are posting big moves after the bell.Market Insiderread more
(Adds Takeda statement, details on Xiidra, background)
May 8 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidra for $3.4 billion, as well as potential milestone payments of up to $1.9 billion, to expand its portfolio of eye care medicines.
The deal is expected to close in the second half of 2019, Novartis said in a statement.
Takeda said separately that the sale is part of its strategy to focus on business areas core to its long-term growth and cut down debt following its acquisition of Shire.
The Japanese company said it is also selling TachoSil, a surgical patch for bleeding control, to Ethicon for about $400 million.
Takeda completed a $59 billion deal to acquire peer Shire in January, joining the ranks of the world's biggest 10 drugmakers by sales - and also becoming one of the world's most indebted.
Dry eye occurs when tears are not able to provide adequate lubrication, and if left untreated, can become extremely painful, leading to permanent damage to the cornea and vision. It is estimated that more than 34 million people in the United States are affected.
Novartis said it will take on about 400 employees associated with Xiidra, which earned $400 million of revenue in 2018.
Xiidra, which is approved to treat signs and symptoms of dry eye in the United States, Canada and Australia, would bolster Novartis' front-of-the-eye portfolio and ophthalmic leadership, the company said. (Reporting by Tamara Mathias Arundhati Sarkar in Bengaluru; Editing by Anil D'Silva and Leslie Adler)